News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Phase 2b Results Of Anergis' Lead Compound Allert To Be Presented At 2014 American Academy of Dermatology Annual Meeting In San Diego


2/27/2014 8:14:27 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

EPALINGES, Switzerland, February 27, 2014 – Anergis, a company discovering and developing proprietary allergy vaccines, today announced that the detailed Phase IIb results of its allergy vaccine AllerT will be presented during this year’s annual meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) in San Diego, CA.

The oral presentation will be given by Prof. Francois Spertini, MD, Principal Investigator of the trial. Presentation Title: "Ultra-Fast Hypoallergenic Birch Pollen Allergy Vaccine AllerT Is Efficient and Safe: Results Of a Phase IIb Study" Time and Date: Tuesday, March 4, 2014, at 02:45pm PST.

Session: New Forms of Immunotherapy (session no. 5606)
Location: Convention Center, Mezzanine Level, Room 14AB

AllerT is a pharmaceutical-grade vaccine to treat birch pollen allergies via ultra-fast desensitization. The vaccine is based on the IP-protected Contiguous Overlapping Peptides (COP) technology.

About Anergis

Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy vaccines that target commercially attractive indications. Anergis´ vaccines are based on its IP-protected Contiguous Overlapping Peptide (COP) technology. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million people. Anergis’ lead-product AllerT, a vaccine to treat birch pollen allergies, is due to enter Phase III clinical development. Two additional vaccine candidates against ragweed pollen allergies (AllerR) and house dust mite allergies (AllerDM) are in preclinical development. Anergis has raised over CHF 30 million from Renaissance PME/Vinci Capital, Sunstone Capital, BioMedInvest and other investors, including Esperante Ventures and Initiative Capital Romandie/Defi Gestion.

About Anergis´ Contiguous Overlapping Peptides (COP) Technology

The only curative therapy of allergies available today, known as “desensitization” or “Conventional Allergy Immunotherapy” (AIT), is the process of inducing tolerance to the allergen. It requires 3-5 years of treatment and exposes patients to the risk of serious side effects – in particular immediate (<30 min) anaphylactic reactions – which can be life-threatening. With its ultra-fast desensitization, Anergis is shaping the future of allergy treatment. Anergis’ vaccines are based on COPs which reproduce the complete amino acid sequence of the allergen in separate synthetic long peptides. COP allergy vaccines are pharmaceutical quality products that provide the complete allergen sequence covering all T cell epitopes, but do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be administered safely at high doses to induce tolerance to the allergen after only a few injections. This enables desensitization in 2 months as opposed to 3 years. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have demonstrated excellent safety (i.e. no immediate allergic reaction) and immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long-term immune memory).

Contact: Anergis SA CH-1066 Epalinges Vincent Charlon, CEO info(at)anergis.ch Media Inquiries: akampion Dr. Ludger Wess, Ines-Regina Buth Managing Partners Tel. +49 40 88165964 or +49 30 2363 2768 info(at)akampion.com

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES